Atea Pharmaceuticals, Inc. (AVIR)

US — Healthcare Sector

Peers: IMMX CNSP HEPA FRLN AVRO ENVB CWBR ELEV OCEA EFTR

Automate Your Wheel Strategy on AVIR

With Tiblio's Option Bot, you can configure your own wheel strategy including AVIR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol AVIR
Rev/Share 0.0
Book/Share 4.8272
PB 0.6608
Debt/Equity 0.0035
CurrentRatio 19.9433
ROIC -0.3884

MktCap 272998605.0
FreeCF/Share -1.4819
PFCF -2.1633
PE -1.9475
Debt/Assets 0.0033
DivYield 0
ROE -0.3126

Rating B-
Score 2
Recommendation Sell
P/E Score 1
DCF Score 3
P/B Score 4
D/E Score 4

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

AVIR
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today issued the following statement:

image for news Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

AVIR
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 6, 2025, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2024, and to provide a business update.

image for news Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

AVIR
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries.

image for news Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

About Atea Pharmaceuticals, Inc. (AVIR)

IPO Date 2020-10-30
Website https://ateapharma.com
Industry Biotechnology
CEO Dr. Jean-Pierre Sommadossi Ph.D.
Employees 56

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.